**Supplementary Table 3. Grade of evidence about terlipressin compared to midodrine and octreotide for hepatorenal syndrome**

|  |
| --- |
| **Terlipressin compared to midodrine and octreotide for hepatorenal syndrome** |
| **Patient or population:** patients with hepatorenal syndrome**Settings:** hospital**Intervention:** terlipressin**Comparison:** midodrine+octreotide |
| **Outcomes** | **Illustrative comparative risks\* (95% CI)** | **Relative effect(95% CI)** | **No of Participants(studies)** | **Quality of the evidence(GRADE)** | **Comments** |
| Assumed risk | Corresponding risk |
|  | **Midodrine+octreotide** | **Terlipressin** |  |  |  |  |
| **HRS reversal** | **Study population** | **RR 11.67** (1.67 to 81.37) | 48(1 study) | ⊕⊝⊝⊝**very low**1,2 | Downgraded because of risk of bias and inconsistency. |
| **48 per 1000** | **556 per 1000**(80 to 1000) |
| **Moderate** |
| **48 per 1000** | **560 per 1000**(80 to 1000) |
| **survival** | **Study population** | **RR 1.38** (0.77 to 2.48) | 48(1 study) | ⊕⊝⊝⊝**very low**1,2 | Downgraded because of risk of bias and inconsistency. |
| **429 per 1000** | **591 per 1000**(330 to 1000) |
| **Moderate** |
| **429 per 1000** | **592 per 1000**(330 to 1000) |
| **serious adverse event** | **Study population** | **RR 0.78** (0.05 to 11.72) | 48(1 study) | ⊕⊝⊝⊝**very low**1,2 | Downgraded because of risk of bias and inconsistency. |
| **48 per 1000** | **37 per 1000**(2 to 558) |
| **Moderate** |
| **48 per 1000** | **37 per 1000**(2 to 563) |
| \*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).**CI:** Confidence interval; **RR:** Risk ratio;  |
| GRADE Working Group grades of evidence**High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.**Very low quality:** We are very uncertain about the estimate. |
| 1 risk of bias 2 very small patients |